id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1978-N-0023-0020,FDA,FDA-1978-N-0023,"Memorandum of Telephone Conversation between FDA/CDER and Venable, LLP",Other,Memorandum,2006-12-21T05:00:00Z,2006,12,,,2019-09-16T13:06:41Z,,0,0,090000648055fba3
FDA-1978-N-0023-0008,FDA,FDA-1978-N-0023,"Internal Memo from Jeffery Shuren, FDA/Office of the Commissioner, to FDA/DDM (HFA-305) dated December 19, 2006",Other,Memorandum,2006-12-20T05:00:00Z,2006,12,,,2019-10-11T16:36:58Z,,0,0,090000648055f84b
FDA-1978-N-0023-0006,FDA,FDA-1978-N-0023,Letter from FDA to Colleague,Other,Letter(s),2006-09-08T04:00:00Z,2006,9,,,2019-09-27T13:06:58Z,,0,0,090000648055f272
FDA-1978-N-0023-0005,FDA,FDA-1978-N-0023,Skin Bleaching Drug Products For Over-the-Counter Human Use; Proposed Rule,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2006-08-29T04:00:00Z,2006,8,2006-08-28T04:00:00Z,2006-12-28T04:59:59Z,2019-09-26T13:15:35Z,E6-14263,0,0,090000648055f1de